TrialProstate cancer and prostatic diseases2025

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.

Julie N Graff et al.PubMed ↗Publisher ↗

No numbers read from the abstract.